2023
GATA3 expression in primary lung carcinomas: correlation with histopathologic features and TTF-1, napsin A, and p40 expression
Wang M, Chen P, Cai G. GATA3 expression in primary lung carcinomas: correlation with histopathologic features and TTF-1, napsin A, and p40 expression. Human Pathology 2023, 135: 93-98. PMID: 36702357, DOI: 10.1016/j.humpath.2023.01.007.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAspartic Acid EndopeptidasesBiomarkers, TumorCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellGATA3 Transcription FactorHumansLungLung NeoplasmsConceptsLarge cell carcinomaPrimary lung carcinomaSarcomatoid carcinomaCell carcinomaNapsin ALung carcinomaGATA3 expressionTTF-1Non-small cell carcinomaNon-small cell lung carcinomaPrimary non-small cell lung carcinomasPrimary lung cancerSquamous cell carcinomaPanel of immunostainsCell lung carcinomaExpression of GATA3Whole-slide sectionsTMA casesAdenosquamous carcinomaTumor histologyHistopathologic featuresGATA3 stainingLung cancerP40 expressionTumor origin
2019
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, Goldberg SB, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Annals Of Oncology 2019, 30: 1311-1320. PMID: 31086949, PMCID: PMC6683857, DOI: 10.1093/annonc/mdz141.Peer-Reviewed Original ResearchMeSH KeywordsAgedAllelesAntineoplastic Agents, ImmunologicalB7-H1 AntigenBiomarkers, TumorCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmErbB ReceptorsFemaleGenetic HeterogeneityHumansLungLung NeoplasmsMaleMiddle AgedMutationProgrammed Cell Death 1 ReceptorProgression-Free SurvivalRetrospective StudiesTobacco SmokingConceptsEGFR-mutant tumorsMemorial Sloan-Kettering Cancer CenterYale Cancer CenterImmune checkpoint inhibitorsPD-L1 expressionImmune checkpoint blockadeTumor mutation burdenCancer CenterLung tumorsCheckpoint blockadeEGFR mutant lung tumorsMutant tumorsCheckpoint inhibitorsLung cancerMutation burdenImmune checkpoint blockade treatmentLow tumor mutation burdenDana-Farber Cancer InstituteEGFR wild-type lung cancersCheckpoint blockade treatmentCell lung cancerEGFR mutation subtypesSimilar smoking historyCell death 1Lung cancer cases